BIOTECH: Co. to Use Blockchain, Cryptocurrency to Build Database
Dawn Barry recently came on board as president of the startup led by former Illumina executives like herself.
The agreement will expand cancer clinical trials and treatment options in the Coachella Valley.
BIOTECH: Platform Interprets Genetic Data for Targeted Cures
The falling cost of sequencing genomes will generate a data tsunami. Edico Genome stands to make sense of much of it.
Dexcom’s technology consists of a sensor that reads glucose levels just beneath the skin.
HEALTH: Aim Is to Prevent Likely Problems, Cut Costs
Amid an aging population, San Diego hospitals have developed senior-focused emergency department services to improve care, with an eye toward their bottom lines.
In 2015, San Diego’s Receptos sold to Celgene for $7.2 billion. Rather than take it easy or go their separate ways, two Receptos’ executives immediately talked of getting the band back together.
The glucose monitoring company's unaudited revenue was $218 million during quarter ending Dec. 31.
Impact Biomedicines was formed around reviving fedratinib, a drug intended to treat a bone marrow disorder and blood cancer.
The company, formed in 2017, is focused on advanced oil extraction methods.
The companies' first joint therapy will target a genetic disease marked by ammonia accumulating in the blood.